Frost & Sullivan bestows 2017 India Drug Repurposing Technology Innovation Leadership Award to NovaLead Pharma Pvt. Ltd. for its proprietary technology platform for drug repurposing to build a promising pipeline of repositioned drug candidates. The award was received by NovaLead Pharma’s CEO Mr. Supreet Deshpande in presence of distinguished business and industry leaders in a glittering function held on 05 Oct 2017 at ITC Maratha, Mumbai. In 2015, NovaLead Pharma had received the Best Innovation Company BIRAC award from Department of Biotechnology, Government of India.
“NovaLead Pharma Pvt. Ltd. is building a promising pipeline of repositioned drugs by precisely developing and successfully deploying its proprietary technology platform. With the introduction of Galnobax, a generic intravenous drug for diabetic foot ulcer, NovaLead is likely to deliver promising and sustained efficacy, better safety, higher patient convenience at an affordable cost,” mentioned Mr. Vipul Verma, Best Practices Middle East, North Africa & South Asia Frost & Sullivan.
Talking at the occasion, Mr. Deshpande said “It is an honor to receive this recognition from Frost & Sullivan. Being chosen by distinguished jury and globally renowned market research firm, this award is a reaffirmation that NovaLead’s technology approach is unique and its research methodology efficient and cost effective at the same time. It is my honor and privilege to receive this award on behalf of entire NovaLead team, collaborators and shareholders.”